Strides Arcolab is currently trading at Rs. 906.00, up by 9.40 points or 1.05% from its previous closing of Rs. 896.60 on the BSE.
The scrip opened at Rs. 905.95 and has touched a high and low of Rs. 908.00 and Rs. 894.00 respectively. So far 12,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 958.10 on 10-Sep-2012 and a 52 week low of Rs. 367.00 on 20-Oct-2011.
Last one week high and low of the scrip stood at Rs. 927.20 and Rs. 882.60 respectively. The current market cap of the company is Rs. 5,311 crore.
The promoters holding in the company stood at 27.69% while Institutions and Non-Institutions held 54.06% and 18.24% respectively.
Strides Arcolab’s - wholly owned subsidiary - Onco Therapies has received two more ANDA approvals from USFDA for Fludarabine Phosphate for Injection, USP packaged in 50 mg/ 2 mL, Single use vials (25 mg/mg/ mL upon reconstitution) - Lyophilized format and Idarubicin Hydrochloride Injection, 1 mg/ mL -5 mL, 10 mL and 20 mL Single-dose vials. The combined market for the two drugs is approximately $20 million.
Fludarabine is a chemotherapy drug used to treat chronic lymphocytic leukemia (a type of cancer of the white blood cells) in adults.
Idarubicin belongs to the group of cancer-fighting medications known as antineoplastics. Idarubicin is used alone or in combination with other antineoplastic medications to treat leukemia.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1568.85 |
Dr. Reddys Lab | 6536.00 |
Cipla | 1509.40 |
Zydus Lifesciences | 1162.40 |
Lupin | 1769.40 |
View more.. |